Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of EV68-228-N in Healthy Adults
NCT06444048Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EV68-228-N in enterovirus infection (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Experiencing Solicited Adverse Events at 48 hours, Number of Participants Experiencing Unsolicited Adverse Events at Day 29 and 1 more. Started Jun 2024; status: completed.
02
Drugs
EV68-228-N
03
Conditions
enterovirus infection
Beyond the preview
Go deeper on NCT06444048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444048.